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This article describes studies with four peptides, epidermal growth factor (EGF), transform-
ing growth factor alpha (TGF alpha), gastrin-releasing peptide/bombesin (GRP), and gastrin.
The mitogenic and anti-secretory activities of EGF/TGF alpha appear to be mediated by a
single class of high-affinity membrane receptors but may involve different signal transducing
mechanisms. Biological activity of EGF resides in the N-terminal 42 amino acid fragment with
the C-terminal undecapeptide determining binding affinity. A parenteral depot formulation of
an EGF-related peptide or a small molecule agonist of the EGF receptor could have utility in
treating various ulcerative disorders of the gut. Although antagonism of EGF (and thus TGF
alpha) receptors and/or transducing mechanisms is frequently cited as a potential therapeutic
approach tohyperproliferative diseases, blockingthe action ofTGFalpha, GRP, orgastrinwith
neutralizing antibodies or receptor antagonists did not influence the growth of a wide range of
solid tumors in nude mice. These findings suggest that, unless tumor growth displays absolute
dependency on one particular mitogen, antagonism of a specific growth factor is unlikely to
have great effect in cancer therapy.
BACKGROUND
Antagonism of receptors or enzymes has underpinned the development of the
modern pharmaceutical industry, as evidenced by the success of drugs such as
beta-blockers, H2antagonists, andcyclo-oxygenase inhibitors. Althoughmanychronic
diseases, such as hypertension, peptic ulceration, and arthritis, are effectively
controlled by currently available agents, there has been almost no progress in the
drug treatment ofsolid tumors for the past 30years [1]. Currently available cytotoxic
drugs have little or no influence on tumorgrowth or life expectancy and cause severe
side effects. Indeed, such isthe severityofthe side effects causedbyanti-proliferative
therapy that recently introduced hemopoetic growth factors and anti-emetic drugs
have themselves created multi-million dollar markets.
The one exception to this dismal picture is the success of drugs to combat
hormone-dependent disease, pioneered by the development of anti-estrogens for
treatingbreast cancer [2]. Thepossibilityofidentifying other solid tumorsdependent
on a particular mitogenic stimulus has provided an impetus to develop inhibitors of
tumor growth factors. Blocking the action of these mitogens by preventing their
production, byneutralizationwith antibodies, orby antagonists acting on cell surface
receptors or enzymes involved in signal transduction is consistent with the time-
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TABLE 1
Mitogenic Activity ofGrowth Factors in GI Tumor Cell Lines
Cell Line Origin Species EGF GRP G-17
MKN45 Stomach Human +++ ++ +
AR42J Pancreas Rat ++++ +++ ++
HT-29 Colon Human +++ + +
MC-26 Colon Mouse ++ ++ ++
Mitogenic activity was assayed by measuring bromodeoxyuridine (Brdu) or tritiated thymidine
incorporation into DNA and the effects confirmed by an increase in cell number [unpublished data].
honored approach to drug design in other therapeutic areas. This strategy has the
best chance of success when the response in dependent on a single factor, as in an
autocrine growth loop.
This paper describes studies directed at three growth-promoting peptides: the
epidermal growth factor/transforming growth factor (EGF/TGF) alpha family,
gastrin-releasing peptide (GRP/bombesin), and gastrin itself (G-17). All these
peptides are capable ofstimulating proliferation ofgastrointestinal tumor cell lines,
as evidenced by an increase in the rate ofthymidine incorporation into DNA (Table
1). EGF interacts with the same receptor as the more widely distributed mitogen
TGF alpha and is capable of stimulating proliferation in a wide range of cell types
[3]. GRP is produced by human small-cell lung cancer (SCLC), stimulates prolifera-
tion of SCLC cells, and has been proposed as an autocrine growth factor in this
disease [4]. In addition to inhibiting the action of GRP directly, a GRP receptor
antagonist could interfere with the action of G-17 by inhibiting its release. G-17 is
well established as agrowthfactorforgastricfundicmucosa [5]. In the rat, prolonged
elevation in plasma levels associated with continuous acid suppression causes
carcinoid tumors in the stomach [6].
EPIDERMAL GROWTH FACTOR
EGF (human homologue urogastrone) is a 53 amino acid peptide containing three
intramoleculardisulphide bonds(Fig. 1). Themajor sites ofproduction areplatelets,
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FIG. 2. EGF was injected (iv) at the arrow into anesthetized rats at 5.0 ,.g/kg (left-hand panel) or
Heidenhain pouch dogs at 0.1 p,g/kg (right-hand panel); controls received saline. The percentage of
inhibition ofhistamine-stimulated secretion was computed from acid output, measured as the product of
volume and H+ concentration. Values are mean (SEM) of four to six animals per group [unpublished
data].
togetherwith salivary and Brunner's glands fromwhere it is secreted into the gut [7].
EGF interacts with the same receptor and activates the same intracellular signaling
pathway as TGFalpha,withwhich it shares about40 percent sequence homology [8].
In addition tocellsofepithelial origin, EGFis apotentmitogenfor a large numberof
other cell types, including fibroblasts and endothelial cells. As a result, EGF
enhances angiogenesis and wound healing as well as stimulating proliferation
throughout the gastrointestinal tract [3,7,9]. Stimulation of vascular development
can be readily demonstrated by application of EGF to the surface of the chick yolk
sac, a preparation used widely to assay angiogenic factors [10]. EGF is also a potent
inhibitor of gastric acid secretion in humans, laboratory animals, and in vitro
[11,12,13]. The anti-secretory profiles following intravenous (iv) bolus injection of
EGF in the rat and dog are shown in Fig. 2.
EGF stimulates mitogenesis via interaction with a 170 kDa transmembrane
receptor which displays intrinsic tyrosine kinase activity [14]. The N-terminal, 621
amino acid extracellular domain contains cysteine-rich regions, which presumably
equatewiththe ligandbinding site. There is a shortmembrane spanningregion and a
cytoplasmic domain which is autophosphorylated in response to EGF binding and
receptor dimerization [15]. Clustering of receptors, internalization, and their subse-
quent recycling to the cytoplasmic membrane provide a mechanism for regulating
sensitivityofthe cells toexogenous EGF. Less isknown about the signal transduction
mechanism leading to inhibition of gastric acid secretion. In isolated parietal cells,
EGF has been shown to inhibit histamine-stimulated cAMP accumulation and
decrease phosphorylation of the substrates for cAMP-dependent protein kinase
[16,17]. The fact that anti-secretory responses are blocked by pertussis toxin implies
that EGF exerts an anti-secretory effectvia the inhibitory (Ga) GTP-binding protein.
Structure-activity studies were undertaken to determine whether existence of
receptor subtypes could account for the diverse (mitogenic and anti-secretory)
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biological actions of EGF. Progressive enzymic degradation of the C terminus was
used to produce a series of peptides of between 53 and 42 amino acids [18].
Truncation of EGF was accompanied by a parallel reduction in its potency as a
stimulant of mitogenesis and an inhibitor of acid secretion. All the peptides behaved
as full agonists or antagonists. Disruption of tertiary structure by treatment with
mercaptoethanol followed by cysteine carboxyamidomethylation to prevent reforma-
tion ofdisulphide bonds abolished the biological activity of EGF.
The above findings are consistent with a single class of receptors for EGF. The
data would also indicate that the C-terminal undecapeptide determines affinity of
the structurally constrained, 42 amino acid N-terminal domain. Marked differences
were, however, found with respect to the duration of EGF exposure required to
evoke the two biological responses. Thus sequestration of EGF with an antibody up
to ten hours after addition of the ligand inhibited mitogenesis, whereas anti-
secretory activity could only be attenuated if the neutralizing antibody was adminis-
tered prior to EGF [19]. This latter finding demonstrates very rapid transduction of
the anti-secretory signal. It is even conceivable that a monomeric ligand-receptor
complex can inhibit secretion by the parietal cell, as opposed to the receptor
dimerization thought necessary to elicit a mitogenic response.
EGF has the ideal spectrum of biological activity to act as a mediator of mucosal
protection in the upper gastrointestinal tract. Thus rapid inhibition of acid secretion
would serve to limit damage caused by H+ back-diffusion immediately following
injury, while stimulation of proliferation and wound healing would repair damage
and restore mucosal cell mass over the longer term. A proposed protective role for
endogenous EGF is not inconsistent with the lack of biological activity of luminal
EGF, since "absorption" can be induced by superficial damage. For example, EGF
inhibited gastric acid secretion in the rat when instilled into segments of small
intestine in the presence of molar NaCl but not when the peptide was administered
in 0.15 M NaCl [20]. This profile of activity has led us to consider that luminal EGF
may serve a "housekeeper" function with respect to gastrointestinal mucosal integ-
rity.
Appearance of EGF-secreting cell lineages in both the gastric and intestinal
mucosa of man has recently been described in association with the presence of
ulceration [21]. While short-term induction of EGF would serve a reparative
function, continuous over-expression of EGF-related growth' factors could predis-
pose to tumor formation. Increased production ofboth TGF alpha peptide and EGF
receptor have been reported in various human tumors, including gastric cancer [22].
In order to define the role of TGF alpha in an experimental model of breast cancer,
MCF7 tumors were grown in athymic mice and the animals treated with a TGF alpha
antiserum prepared by a method similar to that employed to generate EGF antise-
rum [18]. Despite clear evidence for suppression ofTGF alpha activity, tumor growth
was not inhibited [Gregory H, Garner A: unpublished observations]. Because of the
negative result obtained in this tumor growth study and in similar in vivo studies with
GRP and gastrin-sensitive tumors described below, we have been extremely careful
tovalidate each stage of the experiments. Thus the cell culture was shown to respond
to TGF alpha in vitro and the antiserum shown to block this mitogenic effect.
Furthermore, in vivo activity and duration of action of the antiserum was established
in a separate series of experiments from a dosing regime which completely abolished
the anti-secretory effect ofTGF alpha in mice.
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FIG. 3. The GRP/bombesin receptor antagonist ICI 216,140 at 2 mg/kg subcutaneously inhibited
bombesin-stimulated pancreatic secretion (left-hand panel) and caused a dose-related inhibition of
bombesin-stimulated amylase output measured after three hours. Values are mean (SEM) offive animals
per group.
GASTRIN-RELEASING PEPTIDE
GRP, first isolated from porcine intestine, shares a common C-terminal amino
acid sequence with the frog skin peptide bombesin [23]. This heptapeptide region is
responsible for agonist activity, including contraction ofsmooth muscle and stimula-
tion ofpancreatic secretion, gastrin release, and cellularproliferation. GRP hasbeen
proposed to act as an autocrine growth factor in human small-cell lung cancer
(SCLC), based on the presence of GRP-like immunoreactivity in tumor biopsies,
existence ofGRP receptors on SCLC cells, the ability ofGRP to stimulate growth of
SCLC clones, and, seemingly most convincing, the ability of a GRP monoclonal
antibody to inhibit growth of SCLC tumors in nude mice [24]. These findings led a
number of pharmaceutical companies to search for GRP receptor antagonists as
potential therapeutic agents for SCLC.
Assays for displacement of 1251-GRP binding and inhibition of GRP-mediated
3H-thymidine incorporation were developed in 3T3 fibroblasts and used to screen
synthetic peptides [25]. Active compounds were evaluated in vivo for their ability to
inhibit GRP-stimulated pancreatic secretion in rats in order to select potent,
long-acting analogs for screening against human SCLC xenografts in nude mice.
Systematic synthesis of truncated and side-chain deletion analogs of the GRP
(18-27) sequence and screening of substance P antagonists led to identification of
specific GRP antagonists with in vitro activity in the nM range. Further structural
modifications led to the identification of analogs which inhibited GRP-stimulated
amylase output and displayed a prolonged duration of action in vivo [26]. One such
compound, ICI 216,140, with the structure (CH3)2CHCO-His-Trp-Ala-Val-D-Ala-
His-Leu-NHCH3 , was studied in detail. This compound was a very effective antago-
nist of GRP in vivo (Fig. 3). It failed, however, to inhibit the growth of a range of
SCLC tumors in animals.
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While ICI 216,140 did not display activity against tumors in which GRP was
allegedly an autocrine growth factor, it is proving to be a useful tool in terms of
defining the biological actions of GRP [27,28]. For example, we have investigated
gastro-pancreatic reflexes in the anesthetized turkey. In this model, distention of the
proventriculus with a solution of peptone produces an increase in pancreatic
electrolyte and protein secretion. This reflex response was inhibited by a GRP
antagonist but not by antagonists ofacetylcholine, CCK, or gastrin. Thus protein-rich
solutions in the avian stomach appear to cause the release of GRP, which then acts
directly on the pancreas to stimulate secretion. This finding may indicate a wider role
for GRP in mediating the gastric phase of digestion.
GASTRIN
Gastrin (G-17) is well established as a stimulant of fundic mucosal growth [29].
Although exogenous G-17 is capable of stimulating proliferation ofvarious intestinal
cells in vitro, there is little evidence to suggest this hormone plays any significant role
in regulating mucosal proliferation elsewhere in the gut. In the stomach, hypergas-
trinemia in response to G-17 or to hypochlorhydria induced by surgical or pharmaco-
logical means have each been reported to cause hyperplasia of antral G cells and
fundic ECL cells [30,31]. The latter topic has been a focus of attention as a
consequence of the finding that long-term administration of omeprazole and other
potent inhibitors of acid secretion induces carcinoid tumors in rats [32]. Further-
more, procedures which elevate G-17 have been reported to stimulate the growth of
gastrointestinal (GI) tumor cell lines and to promote formation of chemically
induced tumors in animals [33,34]. There are also reports that postprandial levels of
G-17 are elevated in patients with colon cancer [35]; however, any link between
hypergastrinemia and GI cancer in man remains circumstantial.
More convincing evidence for a causal role of G-17 in tumorigenesis would be
provided by a demonstration of tumor regression after blocking the action of
endogenous G-17 with receptor antagonists or by neutralization with antibodies.
Since these tools are now available, we have investigated their influence on growth of
a range of GI tumors in vivo and in vitro. Four transformed GI cell lines were used;
MKN45 (human gastric), AR42J (rat pancreatic), MC26 (mouse colonic), and C523
(human colonic). Presence of high-affinity G-17 binding sites on these cells and/or
stimulation of proliferation by 0.1-1 nM G-17 were used to indicate the presence of
functional receptors. For in vivo studies, the GI cell lines were grown as xenografts in
athymic mice and the effects of gastrin antagonism determined. Three different
strategies for inhibiting the action of gastrin were used: the synthetic receptor
antagonist L365260 [36], a monoclonal CURE Gas-93 (kindly provided by Dr. John
Walsh), and an antiserum raised in sheep against gastrin 2-17 linked to keyhole
limpet hemocyanin [37]. Prior to investigating anti-tumor activity, all treatment
regimes were shown to inhibit gastrin-stimulated acid secretion in mice. With the
exception of a statistically significant inhibitory effect of the antiserum against
growth of AR42J and C523, none of the treatments influenced tumor growth, as
summarized in Table 2. Although these findings are largely negative, G-17 is but one
of numerous circulating mitogens capable of stimulating growth of experimental
tumors. As proved to be the case with TGF alpha and GRP, it seems equally unlikely
that inhibiting G-17 will have a major effect in the therapy of cancer.
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TABLE 2
Effect ofGastrin Antagonism on Tumor Growth in Nude Mice
Treatment MKN45 AR42J C523 MC26
L365 260 Inactive Inactive Inactive Inactive
G(2-17)antisera Inactive Active Active Inactive
CURE Gas-93 Inactive Inactive Inactive Inactive
Growth of four GI tumor lines in groups of seven to ten nude mice was assessed after 18-36 days of
treatment with a gastrin receptor antagonist (L365260) or two different immunoneutralization strate-
gies [37].
SUMMARY AND CONCLUSIONS
EGF interacts with the same receptor and shares the same profile of biological
activity as TGF alpha, including inhibition of gastric acid secretion, stimulation of
cellular proliferation, and enhancement of wound repair. Evidence from binding
studies andbiological activityofaseriesoftruncated EGFpeptides suggestsboththe
rapid (anti-secretory) and prolonged (trophic) actions are mediated via a single class
of receptors. In the gastrointestinal tract, EGF receptors are restricted to the
basolateral membrane ofmucosal cells, which probably accounts for the lack oforal
activity of EGF and TGF alpha. A parenteral slow-release formulation or an orally
active small molecule mimetic could, however, have utility in treating various
ulcerative diseases.
Antagonizing the action of EGF/TGF alpha has also been proposed to have
therapeuticpotential, in this case as a treatment forsolid tumors. Thusbothpeptides
stimulate proliferation ofawide rangeofcelllines andenhance tumorgrowthinvivo.
Similar findings have been made with a number of other peptides, including
GRP/bombesin and G-17. Growth ofvarious transplanted tumors in nude micewas,
however, unaffected by antagonism of these peptides, suggesting that strategies
which seek to block the action of single mitogens will have little effect in cancer
therapy.
The literature contains many accounts ofstudies in which tumor growth has been
accelerated by administration of a particular mitogen and the response then inhib-
ited by co-administration of the corresponding antagonist. Such experiments are
largely self-fulfilling, and provide little to support the use of growth factor antago-
nists in anything other than "autocrine" disease. Nevertheless, development of
neutralizing antibodies and receptor antagonists to these regulatory peptides will
continue to enable important findings to be made concerning their physiological
roles and possible therapeutic uses. Thus stimulation ofgastric secretion by neutral-
ization of circulating EGF suggests the parietal cell is subject to tonal inhibition by
EGF in vivo. Similarly, inhibition of pancreatic secretion in response to gastric
distention by a GRP antagonist suggests that GRP may have a role in mediating the
gastric phase ofdigestion.
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